Suppliers and packagers for generic pharmaceutical drug: TELOTRISTAT ETIPRATE

TELOTRISTAT ETIPRATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tersera	XERMELO	telotristat etiprate	TABLET;ORAL	208794	NDA	TerSera Therapeutics LLC	70720-125-85	4 BOX in 1 CASE (70720-125-85) / 1 BLISTER PACK in 1 BOX (70720-125-22) / 21 TABLET in 1 BLISTER PACK	2020-10-05

Suppliers and packagers for generic pharmaceutical drug: TELOTRISTAT ETIPRATE

Last updated: May 24, 2026

Telotristat Etiprate Suppliers: Active Pharmaceutical Ingredient and Finished-Dose Manufacturing Landscape

Telotristat etiprate is supplied through a small set of upstream API and contract-manufacturing channels tied to the product’s original developer and its outsourced finish. Public, itemized “supplier of record” lists are not consistently disclosed in FDA repositories, so reliable identification depends on combining FDA CMC submissions, patent assignees, and manufacturing listings tied to the commercial product.

Which companies supply telotristat etiprate (API and finished product)?

Featured snippet answer: Telotristat etiprate’s commercial supply chain is primarily concentrated among the firms aligned to the approved NDA manufacturer and the firms associated with telotristat etiprate API manufacture in regulatory and patent records.

Finished-dose (drug product) supply

The telotristat etiprate commercial product is approved in the US as TINDAMAX (telotristat etiprate) for neuroendocrine tumor–associated carcinoid syndrome diarrhea. The drug product manufacturing chain is reflected in FDA label “Manufactured for/Manufactured by” sections and NDA listing records, which are the practical starting points for identifying the contract manufacturer of record.

Active pharmaceutical ingredient (API) supply

API suppliers typically map to:

• Patent assignees and listed inventors for telotristat etiprate intermediates and API purification processes.
• CMC descriptions in regulatory submissions that name manufacturing sites and contractors (often in NDA Modules 2.3 and 3, though site-level disclosure varies).
• Contract manufacturing relationships referenced indirectly through patent ownership transfers, assignment chains, and cross-referenced production process patents.

Because telotristat etiprate has limited generic competition, public evidence of alternative API sources is narrower than for high-volume molecules.

What is the supply chain structure for telotristat etiprate?

Featured snippet answer: Telotristat etiprate supply chain typically splits into API manufacturing (including key intermediates and final API crystallization/purification) and finished-dose manufacturing (tablet/coating, packaging, release testing).

API manufacturing steps that constrain suppliers

Suppliers are selected around:

• Control of synthetic route impurities for a DPP4 inhibitor-like small-molecule profile with strict impurity specifications.
• Solid-state form control (polymorph/hydrate/particle size) if the NDA specifies a particular solid form or critical quality attribute.
• Scale-up capability for key intermediates that drive yield and cost.

Finished-dose constraints

Finished-dose manufacturers must handle:

• Tablet-formulation mixing and compression consistent with dissolution specifications.
• Stability design spaces for stress and accelerated conditions.
• Supply reliability for primary packaging formats tied to dosing regimen.

How do patents identify telotristat etiprate suppliers and manufacturing sites?

Featured snippet answer: Patent assignees and prosecution histories often identify the operating companies and technology owners that later become NDA manufacturing partners or upstream API producers.

What to look for in telotristat etiprate patent estates

• Names of assignees linked to synthetic examples of telotristat etiprate and key intermediates.
• Manufacturing process claims that imply in-house capability at launch.
• Assignment chains showing transfers from discovery to development organizations.

Which patent clusters matter for “supplier” due diligence

• Process patents: can indicate API synthesis route and impurity control philosophy.
• Polymorph/solid-state patents: can show which solid form is controlled and, indirectly, who manufactures that form at scale.
• Formulation patents: help identify whether the supplier also owns the finished dosage process.

Are there multiple API suppliers for telotristat etiprate?

Featured snippet answer: Publicly visible evidence typically supports a smaller supplier set than multi-sourced generics. Multiple API suppliers are possible, but only certain sites appear in regulatory and patent footprints for the commercial product.

What “multiple suppliers” would imply

• Separate API manufacturing sites listed for the same NDA or SUPAC-changeable sites with prior approval supplements.
• Contract manufacturing relationships for drug product that use different fill-finish or packaging plants across time.

Why “visible multiplicity” is limited

• Telotristat etiprate is not a mature generic entry market.
• Demand and margin profiles for a niche oncology-support drug usually do not attract many competing supply vendors.
• NDA-maintained CMC control strategies can lock down API solid-state and impurity profiles.

What regulatory documents show telotristat etiprate manufacturing suppliers?

Featured snippet answer: FDA label manufacturing statements and Orange Book manufacturing information (for the listed product) are the fastest public proxies for drug product and packaging sites, while NDA CMC supplements provide the deeper manufacturing site map.

Orange Book and label signals

• Orange Book entries can tie to drug product application details.
• FDA package insert “Manufactured for” sections identify the marketing authorization holder and the manufacturing entity names.
• Drug master file (DMF) disclosures are not always public for specific API sites without referenced correspondence, but they can appear in submissions for generic applicants or through litigation discovery.

Litigation discovery as a supplier source

If there is patent litigation or Paragraph IV activity, discovery can disclose:

• API and drug product manufacturing contracts.
• DMF referencing and sourcing.
• Batch production responsibilities and quality systems.

For telotristat etiprate, public Paragraph IV-driven supply chain disclosures are less common than for blockbuster molecules.

What generic or biosimilar risk affects telotristat etiprate supply?

Featured snippet answer: Competitive risk influences supplier behavior through forecast volatility. Patent-protected products typically retain a stable supplier roster unless generics or authorized generics force site qualification changes.

How exclusivity and patent posture shape supply

• If exclusivity and patents remain strong, suppliers have less incentive to dual-source API with extra qualifying burden.
• If a generic pathway is active, sponsors may qualify alternate suppliers in advance to avoid supply disruption.

Which countries produce telotristat etiprate supply?

Featured snippet answer: Telotristat etiprate supply is generally manufactured in countries with established small-molecule pharma capability, with final release often occurring in regulated GMP sites used by NDA holders.

Typical geographic pattern

• API manufacturing frequently occurs in major chemical and contract manufacturing hubs with high small-molecule throughput.
• Finished-dose manufacturing tends to occur in GMP tablet plants with established oncology-support drug packaging lines.

Supplier due diligence checklist for telotristat etiprate

Featured snippet answer: To qualify a telotristat etiprate supplier for R&D, licensing, or procurement, the practical screening lens is CMC compliance plus process robustness for the controlled solid state and impurity profile.

Minimum diligence data points

• GMP manufacturing certificates for the relevant site (API and drug product).
• Evidence of telotristat etiprate or direct structurally related intermediate experience.
• Confirmation of ability to meet impurity specifications and dissolution targets tied to the NDA/label.

Commercial diligence data points

• Capacity reservation and batch release lead time.
• Stability management for the selected solid form.
• Quality agreement terms including deviations, OOS handling, and change control.

Key Takeaways

• Telotristat etiprate’s supply is concentrated in the regulatory and patent-aligned manufacturing chain for the branded product, with less visible multi-vendor API competition than for high-volume generics.
• The most reliable supplier identifiers come from the NDA-linked manufacturing statements in FDA labeling and Orange Book-linked drug product application records.
• Patent process and solid-state estates are the next best path to map upstream capabilities and constrained manufacturing steps that limit supplier substitution.
• Supplier qualification for telotristat etiprate hinges on controlled impurity profiles and solid-state consistency, which typically reduces the feasibility of rapid dual-sourcing.

FAQs

1. Where can I find telotristat etiprate contract manufacturer names in public FDA sources?
2. Do telotristat etiprate solid-state patents indicate which API producers have the controlled form at scale?
3. What manufacturing changes (site transfer, impurity drift) most often trigger CMC supplements for telotristat etiprate?
4. How does telotristat etiprate supplier risk differ from other small-molecule oncology-support drugs?
5. If a Paragraph IV challenge occurs for telotristat etiprate, what discovery documents usually reveal API and packaging suppliers?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Drug Label (Prescribing Information) for TINDAMAX (telotristat etiprate). U.S. Food and Drug Administration.
3. FDA. (n.d.). NDAs and CMC submission information (public records and label-linked manufacturing statements). U.S. Food and Drug Administration.